Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Trading at least tightened up on TOOT today.
Cyalume Technologies Closes $3.5 Million Private Placement
Cyalume Technologies Holdings, Inc. announced today that it has closed the sale of 871,823 shares of common stock to institutional investors in a private placement at a price of $4.60 per share. The consideration paid by investors consisted of approximately $3.5 million in cash and the cancellation of 1,015,000 public warrants, which were valued at $0.50 per warrant.
The Company will use the net proceeds of the private offering to fund general corporate purposes.
Derek Dunaway, President and CEO of Cyalume Technologies, Inc., said, "This investment will bolster our ability to execute on all of the growth opportunities that we are seeing in the ammunition business."
The Cost of Diagnostics Versus the Cost of a Young Athlete’s Life
The title may have grabbed a reader’s attention and that was its purpose. All too often press releases that come from developmental companies are simply overlooked in the investment community as it doesn’t have a direct impact on today’s share price for the given company. Being an investor does not disassociate a person and their lives as a parent, relative, friend or even just an acquaintance to others; in short, a person. With that comes a freedom, and perhaps even an obligation, to speak out and share information with others that stem from the investment community and are important on a more global level that may have been casually overlooked in the news section of a financial publication by most.
A recent press release by Vicor Technologies, Inc. (OTCBB:VCRT) is the exactly this sort of literature that carries with it a plethora of thought-provoking sentences for all to ponder and absorb. Based on the accomplishments of Steve Watts, Director of Sports Medicine at Vicor, he could certainly be labeled an “industry expert” as his list of accolades and positions is long and distinguished, including Visiting Professor in Sports Medicine in the Division of Surgical & Interventional Science at University College London, a tenured Associate Professor in the UMMC Department of Orthopedic Surgery and Rehabilitation and the Department of Family Medicine, and a man who has made more than 95 presentations on a variety of sports medicine and athlete care topics. Mr. Watts spoke today via the Vicor release on the debate over cardiac screening for young athletes and how it pertains to identifying the potential of a cardiac incident in young athletes.
What was particularly compelling was Mr. Watts’ comment,
“The continuing debate about whether to provide cardiac screening using ECG and echocardiograms to young athletes is primarily based on a simple cost/benefit equation. The naysayers contend that the cost does not justify the end. In other words it is too expensive to save such a relatively small population of young athletes from sudden cardiac death. They reference the relatively small size of the population to receive testing, the rarity of sudden cardiac death in that population, and that there is a higher incidence of sudden cardiac death in the general population that does not receive such testing. In addition, the number of pediatric cardiologists nationwide is not sufficient to adequately address the task. Chief among their concerns is the high cost related to 12-lead ECG testing, and the higher cost of follow-on testing associated with the large number of false-positives it produces.”
Mr. Watts was quick to note that there is conflicting data about the benefit of screening with current methods used (12-lead ECG testing and echocardiogram) and that these diagnostics, while effective to an extent aren’t able to identify all of the causes of sudden cardiac death, but referenced research that proves it is still more proficient in saving young lives than making no effort at all. Some research shows that it is extremely proficient.
Vicor’s PD2i Analyzer, a new technology which has been referred to as “the new vital sign” on some occasions, has demonstrated accuracy in risk stratifying diabetics for the presence of diabetic autonomic neuropathy (DAN), cardiovascular disease patients for death resulting from arrhythmia or congestive heart failure, and trauma victims for imminent death absent immediate lifesaving intervention. In a study performed by the University of Rochester, researchers found that the PD2i Analyzer™ is predictive of total mortality, cardiac death, and heart failure in patients with left ventricular ejection fraction of less than or equal to 35 percent. With a hazard ratio of 2.34 and a P value of 0.023 for congestive heart failure mortality, a hazard ratio of 1.89 and a P value of 0.13 for cardiac mortality, and a hazard ratio of 1.95 and a P value of 0.004 for total mortality, the study results are highly statistically significant and demonstrate the ability of the PD2i Analyzer™ to identify those patients at an elevated risk of total mortality, cardiac mortality, and congestive heart failure death.
Rather than standing there beating his chest about the aspects of the Company’s revolutionary technology that can save lives, the press release was written in a very low-key way and more in the manner of educating the public and investment community as to that state of the industry. It provided information on a subject that is, unfortunately, not in the limelight as it only seems to carry any significance in the eyes of reporters when a star athlete drops over dead. The important thing to note is that not only could that athlete’s life have possibly been spared, but each one of the kids, young adults and college athletes who have suffered the same fatal end.
While, admittedly, not the most common of investment-oriented articles, some things need to be reiterated as to an overall importance on our quality of life. It is really not much different than a biotech seeking a new cancer therapy or a car manufacturer publicizing new safety devices; saving lives is saving lives. The argument over whether it “makes wise financial sense” is certainly worth a much closer look and evaluation before anyone makes an argument that it isn’t.
The complete press release can be read on Yahoo Finance at http://finance.yahoo.com/news/Sports-Medicine-Physician-iw-2022808821.html?x=0&.v=1. More information on Vicor Technologies and its PD2i® algorithm-based products can be found on the Company’s website at www.vicortech.com.
Cyalume Technologies To Host Earnings Conference Call & Webcast
Cyalume Technologies Holdings, Inc. (OTCBB:CYLU) announced today that it invites the investment community to participate in its Annual and Fourth Quarter 2010 Earnings Conference Call and Webcast which will be held on March 28, 2011 at 11:00 AM ET. The event is open to the public where the Company intends to discuss the firm’s results, outlook and related matters.
To attend, participants need to:
1. Dial 1-877-312-7507 or 1-253-237-1164
2. Ask for the "Cyalume Technologies Conference Call, ID No. 50417730”
A simultaneous webcast will also be available on the internet, which can be accessed through: http://investor.cyalume.com/eventdetail.cfm?eventid=94008
For those unable to attend the event live, a replay of the conference call will be available shortly after the call on the Investor Relations page of the company website at: http://investor.cyalume.com/index.cfm.
Both shareholders and non-shareholders are encouraged to attend the event or listen to the replay to keep up to speed with the world leader in chemiluminescent (chemical-light) technology.
Cyalume Technologies suite of visible and non-visible chemical-light products provide dependable training and battlefield operation light solutions to the United States and NATO country militaries, as well as to safety professionals across the globe. Products also include training and tactical chemiluminescent ammunition payloads for both military and commercial markets that offer a non-pyrotechnic, environmentally-friendly alternative to conventional ammunition. Cyalume manufactures its products in West Springfield, Massachusetts and Aix-en-Provence, France. For more information, please visit the Company's web site: www.cyalume.com.
Opus Group Gives Vicor Technologies (VCRT.OB) a “Speculative Buy” Rating
Opus Group Financial, an independent, privately-owned, investment research and advisory firm committed to providing in depth unbiased research, financial advice and execution of development services to private, micro and small-cap companies, released a new rating for Vicor Technologies (OTCBB:VCRT) in February; rating the Company a “Speculative Buy.” The rating equates to the opinion that Opus Group has deemed the long-term prospects of the company are positive and that the risk/reward ratio advocates the purchase of the stock. This rating does carry a bit more risk than a typical “buy” rating due to the possibility of higher degrees of short-term volatility while Vicor continues to stabilize operations and revenues while the share price continues to trade at a discount to market.
It is interesting to note that the well-respected Group sees the trend shift that is happening within Vicor’s business plans and balance sheets. The Research Note published with this updated report focused on Vicor’s accelerating revenue growth which produced $77,000 in the month of January 2011 alone; which outperformed the entire fourth quarter and is a big chunk of the $190,000 reported for the entire year of 2010. Duly noted, revenues are dynamic and can be very volatile, but it cannot be overlooked that the first month of 2011 created a very promising outlook for the year and reflects well upon the decision to increase the Vicor sales force in the second half of 2010.
In maintaining the “Speculative Buy” rating, the report stated,
“We expect to see exponential revenue growth, starting with small initial sales and expanding at a fast rate in the next quarters and years, as market acceptance grows and as recurring revenues become a more substantial part of the company’s revenue streams. Initially, however, we believe that sales will consist mostly of equipment sales as Vicor needs to establish a solid installed base first.”
Vicor is a bio-technology company focused on the development and commercialization of innovative, non-invasive medical diagnostics using its patented, proprietary PD2i nonlinear algorithm and software to stratify patients at risk of sudden cardiac death or autonomic nervous system dysfunction, and trauma victims in need of lifesaving intervention.
Article posted on Pitch Engine
Vicor Continues Expansion; Signs Distribution Agreement in Middle East
Some companies just flutter around trying to strategize how to get operations rolling and others seem to have it all under control with continuously moving forward with operations, revenues and expansion. Vicor Technologies certainly qualifies as the latter of those two types. No catalyst is needed to keep the Company driving forward with advancements with their proprietary PD2i® technology. The groundwork was laid in the prior years and since expanding its sales force in the third quarter of 2010, Vicor has not been shy of announcements showcasing the growth of revenues and distribution.
On Wednesday, February 23rd, Vicor announced another significant move to broaden their footprint globally by signing a distribution agreement with Hadar Training and Medical Services to serve as its exclusive agent for marketing and sale of its PD2i Analyzer™, PD2i CA™(Cardiac Analyzer) and PD2i VS™ (Vital Sign) in Israel and Palestine. Operating since 1987, Hadar is an industry leader in providing first aid, resuscitation, EMT and Advanced Trauma Life Support (ATLS) as well as trauma training and medical programs. Hadar is also a leader in the importation and marketing of emergency medical equipment to community and field hospitals, and in the conversion and supply of mobile intensive care units and ambulances.
This new agreement is a perfect fit for Vicor and its revolutionary technology that has been dubbed “the new vital sign” given its propensity to accurately diagnose trauma patients and risk stratify specific target populations for future pathological events, including diabetics for the presence of diabetic autonomic neuropathy (DAN), cardiovascular disease patients for death resulting from arrhythmia or congestive heart failure, and trauma victims for imminent death absent immediate lifesaving intervention.
Vicor CEO David Fater commented,
"We're extremely pleased to have HADAR representing our PD2i® products. Hadar is a leader in the importation and marketing of emergency medical equipment to the Israeli community and field hospitals. Hadar will obtain approval from the Israel Ministry of Health and any other required regulatory authorities for the marketing of our products at its expense. We are confident that Hadar will be successful in securing the necessary regulatory approvals for our products as quickly as possible and are excited by the prospect of having our PD2i® products made available throughout the Israeli emergency medical community.”
As mentioned, Vicor is motivated and expanding rapidly and doing it while keeping its share structure firmly intact. With only approximately 46 million shares outstanding and less than 37 million in the float, investors may soon be taking notice of the Company as the PD2i®-based products continue to be used worldwide; which could lead to future press releases along the lines of the one announced two weeks ago detailing revenues from January 2011 topping totals from the whole fourth quarter of 2010.
More information on Vicor Technologies and its PD2i® technologies can be found on the Company’s website at www.vicortech.com. Investors can learn more about Hadar Training and Medical Services www.hadar-medical.co.il/len/.
CEO Alan Shortall and Unilife Featured in “ONdrugDELIVERY,” the Niche Market Specialist on Drug Delivery
ONdrugDELIVERY is a series of publications from Frederick Furness Publishing with each issue focusing on a specific topic within the world of drug delivery that is supported by industry experts in the featured field. The latest edition is titled “Prefilled Syringes: Primary Packaging with Substantial Benefits” and focused its attention on a select few industry leaders within the prefilled and safety syringe markets.
Unilife Corporation (NASDAQ:UNIS) shined with its portion of the publication entitled, “Differentiation Without Disruption,” in which Unilife CEO Alan Shortall explained how the Unifill syringe has set a new standard in safety and efficiency by converging therapeutic drugs and innovative devices into a truly unique combination product. In an already highly competitive market, regulatory standards are becoming ever-increasingly stiff which is driving costs higher for biotechs to bring products to market. This, coupled with pressures from governments to reduce overall costs of products to assist in healthcare reform, has put most companies in the position of taking a more aggressive role in pursuing cost-cutting measures and corporate optimization. As Mr. Shortall explains, the Unilife products are a perfect fit for companies that are looking to maximize efficiency across a broad spectrum of business strategies, not to mention addressing compliance issues as government mandates are being steadily passed to protect healthcare workers throughout the United States and Europe. To name a few of the many proven benefits, the propriety Unilife Unifill syringes:
• Eliminate unnecessary waste with regards to storage, shipping and packaging
• Create strong brand differentiation against entrenched competition
• Enhance patient care
• Increase safety exponentially by virtually eliminating the risk of infection form potential transmission modes such as needlestick injuries or aerosol.
The article touched on a wide array of topics that not only explained the industry in general, including the rapid growth rate, but also discussed the evolution of the industry that has led to Unilife’s state-of-the-art combination product. Additional comparisons with ancillary products and affiliated flaws that not only affect overall performance, but also drive costs higher across the board were also a primary focus of the Unilife article.
The history of Unilife’s relationship with Sanofi-Aventis was also detailed explaining how the two forward-thinking companies have worked together for the last seven years bringing the device from concept to product as the world’s first and only known primary drug container with safety features that are fully integrated within the glass barrel. Sanofi’s commitment to Unilife and support to bring the syringes to market have helped not only the development of Unilife, relocation to a new 165,000 sq. ft world headquarters and the transition to the NASDAQ markets, but also assisted to secure the future of Unilife for many years to come. Investors and businesses alike are encouraged to read the complete article to learn more about Unilife Corporation and the multitude of unparalleled benefits of the Company’s syringes at http://www.ondrugdelivery.com/publications/Prefilled%20Syringes%20Feb%202011/Prefilled%20Syringes%20February%202011%20hi%20res.pdf.
Nice move today: Video Stock Chart here on Ihub: http://ih.advfn.com/videos/stock-chart/lvlt-video-chart-2-16-11_qS6asS105jY
Cyalume Technologies: Addressing the Environmental Protection Agency’s Concerns With Innovative Light Technology
Everyone knows what traditional roadside flares are. If you don’t have them in your car, you might want to look into acquiring a few as they provide critical safety light to alert oncoming traffic at accident scenes and vehicle breakdowns. The only problem is that traditional roadside flares present many safety and environmental issues. In fact, government agencies and commercial companies have in recent years begun to move away from using conventional incendiary flares due to the pollution, fire hazards and liability that they can cause. Now the Environmental Protection Agency (EPA) has voiced concern over one of the principal chemicals found in these flares, perchlorate. Fortunately, Cyalume Technologies (OTCBB:CYLU), the world leader in chemical-light technology, developed the SnapLight® 8” Flare Alternative product to address these concerns.
In speaking before a Senate committee in the end of January, the EPA’s Administrator Lisa Jackson announced that the EPA would move to curb the levels of perchlorate found in drinking water throughout the United States. Perchlorate, both a naturally occurring and man-made chemical that is used in the manufacture of rocket fuel, fireworks, explosives and the aforementioned roadside flares, has been linked to thyroid problems in pregnant women and young children. According to the EPA, data show that in the U.S. more than 4 percent of public water systems have detected perchlorate and between 5 million and 17 million people may be served drinking water containing perchlorate. Fortunately for the millions of safety professionals and consumers who depend on traditional roadside flares there is an alternative product on the market that directly addresses the EPA’s concerns. Cyalume’s patented environmentally-friendly Next Generation Flare™ uses non-toxic ultra high-intensity chemical-light that is 100% perchlorate-free. The SnapLight® 8” Flare Alternative with reflective strip enhances visibility up to one mile. Since it is not pyrotechnic, it cannot cause the hard to extinguish fires associated with conventional flares. More information about the product can be found by visiting: www.flarealternative.com.
While representing only a small part of its overall business, the SnapLight® 8” Flare Alternative product is a great example of Cyalume’s successful track record of bringing to market innovate new products that leverage the breakthrough advancements the Company has made in its underlying chemical-light technology. For example, the company just recently announced the launch of a new chemical-light shotgun shell tracer that targets the large global sports shooting market. In addition, the Company is partnering with General Dynamics to develop a whole host of small, medium and large caliber ammunition projects that target the multi-billion dollar military ammunition market. As the exclusive supplier to militaries in the U.S. and NATO countries for all of their chemical-light products and with a strategy of bringing to market unique environmentally-friendly products, Cyalume is poised for continued success.
Great article on Cyalume: Cyalume Technologies: An Innovative Light Company that Deserves a Spotlight
All too often in the small and mid-cap markets, “less-than-deserving” companies are surrounded by a frenzy of investors speculating about the potential of a company. On other occasions, solid companies go relatively unnoticed by the investment community for no apparent reason. Cyalume Technologies (OTCBB:CYLU), the world leader in chemiluminescent (chemical-light) technology, is one of the under-recognized gems in the small cap space. The Company provides innovative chemical-light products to the U.S. and NATO country militaries as well as to the safety industry including policemen and firemen. Given the Company’s recent progress in advancing its core light technology and incorporating it into new products, it deserves a spotlight to examine where the Company is today and can be in the future. For this however, we will just take a quick look at one of Cyalume’s new products, but understand that the Company’s core-military and ammunition businesses are well-established.
The New Fiocchi Chemical Tracer
Cyalume recently announced a strategic agreement with Fiocchi Ammunition USA, a world leader in the field of small-caliber ammunition to develop and market the Chemical Tracer, the world's first non-pyrotechnic shotgun tracer. The Chemical Tracer creates a daytime visible trace that travels with the cloud of the shot allowing shooters to instantly determine their accuracy and therefore correct their aim. This product is evolving quickly and has the potential to, excuse the pun, take off like a bullet from a gun. It was recently the focus of an article on www.shotgunworld.com with a video displaying the technology that can be viewed at http://www.shootingsportsretailer-digital.com/shootingsportsretailer/201101#pg5. The article included some scintillating comments about the likelihood of taking target shooting to the mainstream public as a spectator sport, much like ESPN did with bass fishing when it transformed the sport into the billion-dollar industry that it is today. Perhaps it is not too early to speculate that Cyalume will be on the cutting edge of transforming skeet, trap and sporting clay shooting into a major spectator sport?
The Chemical Tracer represents a significant incremental growth opportunity for Cyalume as the community of sport as well as military and law enforcement shooters worldwide numbers in the millions. In fact, according to a National Shooting Sports Foundation survey, in 2009 over 8 million Americans participated in sporting clay shooting. Although specific data on how many individual shotgun shells were fired by these users is hard to come by, various estimates have put the figure at over 800 million. Capturing only a small percentage of that market will provide Cyalume with a robust revenue stream. Cyalume's decision to partner with Fiocchi to develop and bring to market this new tracer round ensures the optimal exposure and therefore success of this new innovative product.
As we mentioned, the Fiocchi Chemical Tracer highlighted here represents just one of the many innovative products that Cyalume currently manufacturers. With a market cap still under $100 million and exciting new products such as the Fiocchi Chemical Tracer coming to market, Cyalume is certainly deserving of its moment in the spotlight.
Vicor was recently in published in Clinical Neurophysiology. We are looking into reading the complete article.
The Abstract:
Nonlinear PD2i heart rate complexity algorithm detects autonomic neuropathy in patients with type 1 diabetes mellitus.
Skinner JE, Weiss DN, Anchin JM, Turianikova Z, Tonhajzerova I, Javorkova J, Javorka K, Baumert M, Javorka M.
Vicor Technologies, Inc., Boca Raton, FL, USA.
Abstract
OBJECTIVE: The aim of this study was to test whether a new heart rate variability (HRV) complexity measure, the Point Correlation Dimension (PD2i), provides diagnostic information regarding early subclinical autonomic dysfunction in diabetes mellitus (DM). We tested the ability of PD2i to detect diabetic autonomic neuropathy (DAN) in asymptomatic young DM patients without overt neuropathy and compared them to age- and gender-matched controls.
METHODS: HRV in DM type 1 patients (n=17, 10 female, 7 male) aged 12.9-31.5years (duration of DM 12.4±1.2years) was compared to that in a control group of 17 healthy matched probands. The R-R intervals were measured over 1h using a telemetric ECG system.
RESULTS: PD2i was able to detect ANS dysfunction with p=0.0006, similar to the best discriminating MSE scale, with p=0.0002.
DISCUSSION: The performance of PD2i to detect DAN in asymptomatic DM patients is similar to the best discriminative power of previously published complexity measures.
CONCLUSIONS: The PD2i algorithm may prove to be an easy to perform and clinically useful tool for the early detection of autonomic neuropathy in DM type 1 patients, especially given its minimal data requirements.
The Press Release:
Study of Vicor Technologies' PD2i(R) Nonlinear Algorithm as Measure of Diabetic Autonomic Neuropathy to Be Published in Clinical Neurophysiology
BOCA RATON, FL--(Marketwire - 01/12/11) - David H. Fater, CEO of Vicor Technologies, Inc. (OTCBB:VCRT), today announced that Vicor has received notice that a manuscript detailing a study of the ability of its PD2i Analyzer™ to detect the presence of autonomic neuropathy in individuals with type 1 diabetes mellitus has been accepted for publication in Clinical Neurophysiology. Vicor Technologies (http://www.vicortech.com/) is a biotechnology company focused on the development of innovative, non-invasive medical devices using its patented, proprietary PD2i® nonlinear algorithm and software. Vicor is currently in the process of commercializing diagnostics that enable physicians to accurately risk stratify specific target populations for future pathological events, including diabetics for the presence of diabetic autonomic neuropathy (DAN), cardiovascular disease patients for death resulting from arrhythmia or congestive heart failure, and trauma victims for imminent death absent immediate lifesaving intervention.
"Nonlinear PD2i® heart rate complexity algorithm detects autonomic neuropathy in patients with type 1 diabetes mellitus," authored by James Skinner, PhD, Vicor's Vice President and Director of Research, in collaboration with Daniel Weiss, MD, Vicor's Chief Medical Officer, and Jerry Anchin, PhD, Vicor's Vice President and Director of Product Development, details a study to test the ability of Vicor's PD2i Analyzer™, which measures heart rate variability with a PD2i® nonlinear algorithm score, to detect early subclinical autonomic dysfunction in young (12.9-31.5 years) asymptomatic individuals with type 1 diabetes mellitus (DM). The PD2i Analyzer™ demonstrated the ability to detect autonomic nervous system dysfunction very early in asymptomatic type 1 DM patients similar to the best discriminative power of previously published complexity measures. With a P value of 0.0006, the study results are highly statistically significant.
"We are pleased to learn that Dr. Skinner's manuscript, co-authored by our scientific and medical team members, has been accepted for publication in Clinical Neurophysiology, the official journal of the International Federation of Clinical Neurophysiology. The clinical study on which this manuscript is based has once again proven the value of our PD2i Analyzer as a diagnostic that provides physicians with the ability to identify those at risk of future pathological events -- in this case, diabetic autonomic neuropathy -- that might otherwise remain unidentified, and untreated, using traditional diagnostics. More importantly, the PD2i Analyzer™ was able to identify those patients with early subclinical autonomic dysfunction with the results of a resting ECG. To date, the standard of care for diagnosing these patients with a measure of heart rate variability depended on ECGs taken during controlled exercise and paced respiration. Given its accuracy, ease of use, and minimal data requirements, the PD2i Analyzer™ may prove to be a valuable clinical tool for the early detection of autonomic neuropathy in type 1 DM patients," stated Mr. Fater.
Clinical Neurophysiology is the official journal of the International Federation of Clinical Neurophysiology. It is dedicated to fostering research and disseminating information on all aspects of clinical neurophysiology, both normal and abnormal. The journal aims at publishing scholarly reports on human physiology and pathophysiology of both the central and the peripheral nervous system.
About Vicor Technologies, Inc.
Vicor Technologies is a biotechnology company creating innovative non-invasive diagnostics employing its patented, proprietary point correlation dimension algorithm (PD2i®). The PD2i® nonlinear algorithm is a deterministic, nonlinear measure of electrophysiological potentials that predicts future pathological events with a high degree of accuracy in target populations.
Vicor currently has three products employing the PD2i® nonlinear algorithm. The PD2i Analyzer™, which has FDA 510(k) marketing clearance, measures heart rate variability; physicians performing diagnostic tests with the PD2i Analyzer™ are able to receive reimbursement under existing CPT codes. The PD2i VS™ (Vital Sign), in clinical trials under a collaborative effort with the U.S. Army Institute for Surgical Research, risk stratifies combat and civilian trauma victims. The PD2i CA™ (Cardiac Analyzer), in multiple clinical trials, identifies patients at risk of cardiac death.
Vicor anticipates additional applications employing the PD2i® nonlinear algorithm to enable early detection and risk stratification for a variety of other disorders and diseases. Additional information is available at www.vicortech.com.
We will be requesting moderator status for the board so we can update information in the iBox for investors to keep current with Vicor developments and information. On the Vicor website, there is a video in the right-hand corner that gives a glimpse of the PD2i technology. It can be viewed at:
Vicor Website
I have also requested that Stockcharts add CYLU to its database, so we can get the Ibox in order. We will work to get the Ibox current with information and status of operations as well.
This is a video that demonstrates ChemiTracer (pretty cool stuff):
Shooting Sports Retailer
Cyalume Technologies and Fiocchi Ammunition USA to Launch the Fiocchi Chemical Tracer(R) Shotshell at the 2011 SHOT Show in Las Vegas
WEST SPRINGFIELD, Mass., Jan. 10, 2011 (GLOBE NEWSWIRE) -- Cyalume Technologies Holdings, Inc. (OTCBB:CYLU) and Fiocchi Ammunition USA will launch the Fiocchi Chemical Tracer(R), the world's first non-pyrotechnic shotgun tracer at the 2011 SHOT Show in Las Vegas, NV from January 18-21. The Chemical Tracer creates a daytime visible trace that travels with the cloud of shot allowing shooters to instantly determine where they are shooting and how to correct their aim.
The Shooting, Hunting, Outdoor Trade Show and Conference (SHOT Show) is the world's largest and most comprehensive trade show for professionals involved with the shooting and hunting industries. Held at the Sands Expo & Convention Center, the SHOT Show is the world's premier exposition of combined firearms, ammunition and related products with buyers from all 50 states and more than 100 countries. The Fiocchi Chemical Tracer will be on full display at SHOT Show booth 15942.
Cyalume and Fiocchi Ammunition USA, a world leader in the field of small-caliber ammunition entered into a strategic agreement in 2010 to develop and market the Chemical Tracer. This new non-toxic, non-flammable and non-incendiary product-line integrates Cyalume's chemiluminescent light technology into the Fiocchi shotshell to enhance training capabilities for target shooting enthusiasts and law enforcement officers while eliminating the fire hazards and environmental issues associated with conventional tracer applications.
"After a very successful focused pre-launch marketing campaign, Cyalume is excited to introduce the Chemical Tracer to the shooting industry at the 2011 SHOT Show," said Derek Dunaway, CEO of Cyalume Technologies.
"The interest that we received to date from dealers, distributors, retailers and NSCA members is indicative of the value that the Chemical Tracer represents to shooters," said Carlo Fiocchi, Vice-President of Marketing and Sales, Fiocchi Ammunition USA. "We look forward to sharing the innovative training tool with the shooting community at the SHOT Show."
About Fiocchi
Fiocchi Ammunition USA is a subsidiary of Fiocchi Munizioni SpA of Lecco, Italy. A privately held company since 1876, Giulio Fiocchi and his brother Giacomo Fiocchi began as Giulio Fiocchi Enterprise. Following WWII, Fiocchi Munizioni SpA was formed and headquartered in Lecco, Italy. Fiocchi Munizioni SpA, held by Giulio Fiocchi Holdings, produces premium center-fire and shotshell ammunition for law enforcement, hunting and target sports. Globally recognized as the premier ammunition manufacturer, Fiocchi Ammunition USA was established in Ozark, MO in 1983. Fiocchi Munizioni Spa is headed by Stefano Fiocchi, President and CEO and Fiocchi Ammunition USA is headed by Pietro Fiocchi, President. The Fiocchi brand is highly recognized by law enforcement as well as professional and sport enthusiast shooters.
About Cyalume Technologies
Cyalume Technologies is the world leader in the chemiluminescent industry providing dependable light for uses by militaries, police, fire and other public safety organizations in the U.S., NATO countries and the Middle East. Cyalume's chemical lights are depended on in emergencies such as blackouts, industrial accidents, acts of terrorism and natural disasters. Cyalume is the first to manufacture non-toxic, nonflammable, non-energetic and environmental safe chemical light products. A full complement of Military grade Cyalume(R) brand, Industrial grade SnapLight(R) brand and Consumer grade SafetyBright(R) brand emergency lighting solutions are manufactured at its plant in West Springfield, MA.
Support on the flag at $1.05. Looking for a bounce back upward off the 20dma.
Cyalume Technologies Holdings, Inc. Announces New Packaging for SnapLight(R) 8" Flare Alternatives
WEST SPRINGFIELD, Mass., Feb. 1, 2011 (GLOBE NEWSWIRE) -- Cyalume Technologies Holdings, Inc. (OTCBB:CYLU), the world leader in the chemical lighting industry, introduces new foil wrapped SnapLight(R) 8" Flare Alternatives, the Next Generation Flare(TM).
Driven by innovation and continuous improvements, Cyalume has developed new foil packaging for 8" Flare Alternative LightSticks. The new packaging incorporates a layout design that is appealing, user-friendly and makes it easier for customers to identify with the brand and its attributes. Individually foil wrapped for light and moisture protection, the 8" Flare Alternative is ideal for roadside emergency, survival, and safety kits as well as retail outlets.
Developed as a safe, environmentally friendly alternative to traditional flares that are currently used by law enforcement, safety workers, and consumers, the 8" Flare Alternative Ultra High-Intensity lightstick is the new dependable instant light solution. Designed to be practical with an easy to use, maintain, and operate approach, the 8" Flare Alternative has proved useful for safety workers as the Next Generation Flare(TM). The 8" Flare Alternative with reflective strip enhances visibility up to one mile. The attached wire stand allows easy setup and activation.
Unlike traditional flares, the 8" Flare Alternative will not produce heat or flames. It provides 30 minutes of reliable high-intensity light visible up to one mile. Activation is easy with no batteries required. The 8" Flare Alternative meets DOT non-hazardous standards, eliminating hazardous shipping fees.
SnapLight(R) 8" Flare Alternatives are for use at accident scenes, vehicle breakdowns, as hazard markers, and to alert drivers of obstacles in the road. This ultra high-intensity lightstick can be used in wet or dry weather and provides the most visible light in low-light or dark situations. The new, patented formulation provides superior performance in cold and warm climates.
To learn more about the new foil wrapped 8"Flare Alternative, and how it will enhance your current operations, please visit www.flarealternative.com or email info@cyalume.com.
About Cyalume
Cyalume Technologies Holdings, Inc. is the world leader in the chemiluminescent industry providing dependable light for uses by militaries in the U.S. and NATO countries, as well as policemen, firemen, and others throughout the safety industry. Cyalume's chemical lights are depended upon for both military training and battle operations as well as emergencies such as blackouts, industrial accidents, acts of terrorism and natural disasters. A full complement of Military specification ChemLight(R) brand and Industrial grade SnapLight(R) brand emergency lighting solutions are manufactured at their world headquarters in West Springfield, Massachusetts. Their French subsidiary, Cyalume Technologies SAS, manufactures and distributes chemiluminescent products throughout Europe.
Vicor Technologies Names Dr. Steve Watts Director of Sports Medicine
Boca Raton, FL – February 2, 2011 – David H. Fater, CEO of Vicor Technologies, Inc. (OTCBB: VCRT), today announced that Steve A. Watts, MD, was named Director of Sports Medicine, a new part-time position. Vicor Technologies (http://www.vicortech.com) is a biotechnology company focused on the development of innovative, non-invasive medical devices using its patented, proprietary PD2i® nonlinear algorithm and software. Vicor is currently in the process of commercializing diagnostics that enable physicians to accurately risk stratify specific target populations for future pathological events, including cardiovascular disease patients for death resulting from arrhythmia or congestive heart failure, diabetics for the presence of diabetic autonomic neuropathy (DAN), and trauma victims for imminent death absent immediate lifesaving intervention.
“We are very fortunate to have Dr. Watts joining us as Director of Sports Medicine. As Associate Professor in the Department of Family Medicine at the University of Mississippi Medical Center – UMMC is a frequent partner on many of our PD2i Analyzer™ studies -- Dr. Watts instituted the Family Medicine Sports Medicine curriculum and clinical experience at UMMC. He has lectured and written extensively on the treatment and management of a wide variety of sports-related conditions – including head injury and sudden death, which are two established targets for the PD2i Analyzer™. We are extremely gratified to have him working with our scientists and clinical trial partners to validate the ability of our PD2i Analyzer™ to serve as a diagnostic for a range of sports-related disorders,” stated Mr. Fater.
As Vicor’s Director of Sports Medicine, Dr. Watts will oversee clinical trials to test the efficacy of Vicor’s PD2i Analyzer™ to diagnose concussion and other sports-related conditions. Vicor is currently involved in a study to assess concussions in competitive athletes in collaboration with UMMC and Belhaven University. Additional sports condition-related PD2i Analyzer™ clinical trials are currently being explored with additional universities.
Dr. Watts is a tenured Associate Professor in the UMMC Department of Orthopedic Surgery and Rehabilitation and the Department of Family Medicine, where he instituted the Family Medicine Sports Medicine Curriculum and Clinical Experience for resident physicians in the UMMC Family Medicine Residency Training Program. He also serves as Director for the Sports Medicine Fellowship Program, as well as University Sports Medicine staff physician at UMMC, team physician for the Mississippi Braves, Belhaven University Blazers, Provine High School Rams, Lanier High School Bulldogs, and Canton High School Tigers, and a member of the National Rodeo Sports Medicine staff. He was recently awarded an honorary academic appointment as Visiting Professor in the Division of Surgical & Interventional Science at the University College London.
Dr. Watts is a member of the Society of Teachers of Family Medicine, for which he serves on the Sports Medicine Committee; American Medical Society for Sports Medicine, for which he served on the Education Committee; American College of Sports Medicine; the USA Amateur Boxing Association; American Orthopedic Society for Sports Medicine; American Medical Association; Mississippi State Medical Association, the American Academy of Family Physicians; Texas Academy of Family Physicians; and Mississippi Academy of Family Physicians.
Dr. Watts serves on the board of directors of the Mississippi High School Sports Medicine Advisory Committee; Mississippi Academy of Family Physicians, and Mississippi Academy of Family Physicians Foundation. He is a former director of the John Peter Smith Hospital Residency Alumni Foundation; Texas Healthcare Network; Texas Academy of Family Physicians Foundation, and Texas Academy of Family Physicians.
Dr. Watts is board certified by the American Board of Family Practice and is a Fellow of the American Academy of Family Physicians. He holds a Certification of Additional Qualification in Sports Medicine. Dr. Watts earned his MD at the University of Texas Southwestern Medical School. He holds a Texas Secondary Teacher’s Certification in Biology and Chemistry from the University of Houston and a BS in Biology and Chemistry, cum laude, from the University of Houston.
About Vicor Technologies, Inc.
Vicor Technologies is a biotechnology company creating innovative non-invasive diagnostics employing its patented, proprietary point correlation dimension algorithm (PD2i®). The PD2i® nonlinear algorithm is a deterministic, nonlinear measure of electrophysiological potentials that predicts future pathological events with a high degree of accuracy in target populations.
Vicor currently has three products employing the PD2i® nonlinear algorithm. The PD2i Analyzer™, which has FDA 510(k) marketing clearance, measures heart rate variability; physicians performing diagnostic tests with the PD2i Analyzer™ are able to receive reimbursement under existing CPT codes. The PD2i VS™ (Vital Sign), in clinical trials under a collaborative effort with the U.S. Army Institute for Surgical Research, risk stratifies combat and civilian trauma victims. The PD2i CA™ (Cardiac Analyzer), in multiple clinical trials, identifies patients at risk of cardiac death.
Vicor anticipates additional applications employing the PD2i® nonlinear algorithm to enable early detection and risk stratification for a variety of other disorders and diseases. Additional information is available at www.vicortech.com.
Abstract of Study Confirming Predictive Value of Vicor Technologies' PD2i(R) for Cardiac Mortality Accepted for Presentation at American College of Cardiology 60th Annual Scientific Session
BOCA RATON, FL--(Marketwire - 01/25/11) - David H. Fater, CEO of Vicor Technologies, Inc. (OTC.BB:VCRT), today announced that an abstract summarizing the results of a study involving the use of its PD2i® nonlinear algorithm and software to risk stratify congestive heart failure patients has been accepted for the American College of Cardiology 60th Annual Scientific Session and i2 Summit. Vicor Technologies (http://www.vicortech.com) is a biotechnology company focused on the development of innovative, non-invasive medical devices using its patented, proprietary PD2i® nonlinear algorithm and software. Vicor is currently in the process of commercializing diagnostics that enable physicians to accurately risk stratify specific target populations for future pathological events, including cardiovascular disease patients for death resulting from arrhythmia or congestive heart failure, diabetics for the presence of diabetic autonomic neuropathy (DAN), and trauma victims for imminent death absent immediate lifesaving intervention.
Wojciech Zareba, MD, PhD, a Professor of Medicine and Director of the Heart Research Follow-up Program at the University of Rochester Medical Center, will present "Prognostic Significance of PD2i, Novel Risk Marker in Heart Failure Patients" on Monday, April 4, 2011 at 3:30pm during the session titled "ECG/Ambulatory Monitoring - Prognosis in Heart Failure." The American College of Cardiology 60th Annual Scientific Session and i2 Summit will be held at the Ernest N. Morial Convention Center in New Orleans, LA on April 2-5, 2011.
Dr. Zareba was the Principal Investigator on a study titled "Prognostic Significance of Point Correlation Dimension Algorithm (PD2i) in Chronic Heart Failure," which was conducted under a collaborative agreement between Vicor Technologies, and the University of Rochester and the Catalan Institute of Cardiovascular Sciences in Barcelona. The goal of the study was to evaluate the ability of Vicor's PD2i® nonlinear algorithm to predict cardiac events in the 537 chronic heart failure patients enrolled in the MUSIC Trial; MUSIC Trial participants were followed for an average period of 44 months. The conclusion of the University of Rochester researchers who conducted the study is that the PD2i® nonlinear algorithm and software is predictive of total mortality, cardiac death, and heart failure death in patients with left ventricular ejection fraction of less than or equal to 35%. With a hazard ratio of 2.34 and a P value of 0.023 for congestive heart failure mortality, a hazard ratio of 1.89 and a p value of .013 for cardiac mortality and a hazard ration of 1.95 and a p value of .004 for total mortality, the study results are highly statistically significant and demonstrated the ability of the PD2i Analyzer™ to identify those patients at an elevated risk of total mortality, cardiac mortality and congestive heart failure death. Commenting on the study and its results, Dr. Zareba said, "These results are of major importance for risk stratifying heart failure patients who are eligible for therapy with an implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy with defibrillator (CRT-D). Testing heart failure patients using the PD2i® should enhance risk stratification and motivate physicians to implant these devices in ICD/CRT-D eligible patients with abnormal PD2i® test results."
"We're extremely pleased and honored to have this abstract of our MUSIC Trial data study presented at the American College of Cardiology 60th Annual Scientific Session and i2 Summit by Dr. Zareba. While risk prediction is not an approved claim -- the data is under review by the FDA -- we believe the results achieved by the PD2i® nonlinear algorithm in this important study may broaden the market for its use as a diagnostic that will significantly contribute to cardiologists in their assessment of treatment options for heart failure patients. As we steadily advance commercialization of our PD2i® diagnostics, visibility at prestigious conferences such as this enhances our opportunity to explore new strategic relationships and collaborative efforts that may enable us to identify new applications for the PD2i. Additional information about the PD2i® nonlinear algorithm and trials demonstrating its use to identify those at risk of cardiac death -- along with information about how the PD2i® is being used to identify early-stage autonomic nervous system dysfunction and risk stratify trauma victims to improve triage efforts -- may be found at our website: www.vicortech.com," Mr. Fater concluded.
The American College of Cardiology (ACC) is a 39,000-member nonprofit medical society established in 1949 to advocate for quality cardiovascular care through education, research promotion, development and application of standards and guidelines, and to influence health care policy. ACC members are physicians, nurses, nurse practitioners, physician assistants, pharmacists and practice managers. The ACC's Annual Scientific Session and i2 (Innovation in Intervention) Summit features cutting-edge science, innovation, education, networking, intervention.
About Vicor Technologies, Inc.
Vicor Technologies is a biotechnology company creating innovative non-invasive diagnostics employing its patented, proprietary point correlation dimension algorithm (PD2i®). The PD2i® nonlinear algorithm is a deterministic, nonlinear measure of electrophysiological potentials that predicts future pathological events with a high degree of accuracy in target populations.
Vicor currently has three products employing the PD2i® nonlinear algorithm. The PD2i Analyzer™, which has FDA 510(k) marketing clearance, measures heart rate variability; physicians performing diagnostic tests with the PD2i Analyzer™ are able to receive reimbursement under existing CPT codes. The PD2i VS™ (Vital Sign), in clinical trials under a collaborative effort with the U.S. Army Institute for Surgical Research, risk stratifies combat and civilian trauma victims. The PD2i CA™ (Cardiac Analyzer), in multiple clinical trials, identifies patients at risk of cardiac death.
Vicor anticipates additional applications employing the PD2i® nonlinear algorithm to enable early detection and risk stratification for a variety of other disorders and diseases. Additional information is available at www.vicortech.com.
Disclaimer
The appearance of name-brand institutions, such as the American College of Cardiology, ACC Annual Scientific Session and i2 Summit, University of Rochester, and Catalan Institute of Cardiovascular Sciences in Barcelona, and the U.S. Army Institute for Surgical Research, in this media release does not constitute endorsement by institutions of the information, products or services contained therein.
Caution Regarding Forward-Looking Statements
Forward-looking statements in this press release are based on current plans and expectations that are subject to uncertainties and risks, which could cause our future results to differ materially. The following factors, among others, could cause our actual results to differ: our ability to successfully complete the normal range study for PD2i® values; our ability to generate revenues from the sale of the PD2i Analyzer™; our ability to obtain FDA approval of our 510(k) submission to secure a marketing claim for the PD2i CA™(Cardiac Analyzer) for testing patients for cardiovascular disease and our ability to obtain marketing clearance from the FDA for the PD2i VS™ (Vital Sign) for military and civilian applications; our ability to obtain the necessary regulatory approvals to market in the People's Republic of China; our ability to develop additional applications for the PD2i® algorithm; our ability to continue to receive financing sufficient to continue operations and complete critical clinical trials; our ability to continue as a going concern; our ability to successfully develop products based on our technologies; our ability to obtain and maintain adequate levels of third-party reimbursement for our products; the impact of competitive products and pricing; our ability to receive regulatory approval for our products; the ability of third-party contract research organizations to perform preclinical testing and clinical trials for our technologies; the ability of third-party manufacturers to manufacture our products; our ability to retain the services of our key personnel; our ability to market and sell our products successfully; our ability to protect our intellectual property; product liability; changes in federal income tax laws and regulations; general market conditions in the medical device and pharmaceutical industries; and other matters that are described in Vicor's Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and subsequent filings with the Securities and Exchange Commission. Forward-looking statements in this press release speak only as of the date of the press release, and we assume no obligation to update forward-looking statements or the reasons why actual results could differ.